Frontline Nivolumab Plus Chemo Shows Practice-Changing Potential in GI Cancers
March 5th 2021
Yelena Y. Janjigian, MD, discussed the promise of nivolumab plus chemotherapy in patients with PD-L1–positive advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma, as well as important biomarkers that should be used to guide sequencing decisions.